Alyeska Investment Group, L.P. Equillium, Inc. Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.78 - $26.5 $271,928 - $2.59 Million	-97,816 Reduced 38.98%	153,091 $883,000
Q2 2020 Aug 14, 2020	SELL	$2.34 - $3.53 $82,538 - $124,513	-35,273 Reduced 12.33%	250,907 $740,000
Q1 2020 May 15, 2020	SELL	$2.3 - $5.5 $14,234 - $34,039	-6,189 Reduced 2.12%	286,180 $775,000
Q4 2019 Feb 14, 2020	BUY	$3.0 - $5.0 $453,327 - $755,545	151,109 Added 106.97%	292,369 $988,000
Q3 2019 Nov 14, 2019	BUY	$3.31 - $5.6 $165,500 - $280,000	50,000 Added 54.79%	141,260 $536,000
Q2 2019 Aug 14, 2019	BUY	$5.28 - $8.2 $481,852 - $748,331	91,260 New	91,260 $0

11.5M

38.1K

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $47.1M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.